acne inversa Verneuil's disease
Conditions
Interventions
Patients will undergo an I&D or PD depending on the randomization group. After
putting on protective equipment and site preparation, anesthesia is performed
with a field block with 1% lidocaine with
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
16 Years to 64 Years
Inclusion criteria
Inclusion criteria: - Diagnosed with HS - Has an abscess requiring drainage with a maximum diameter of 5 centimeters. - Age 16 years or older - Willing and able to provide informed consent
Exclusion criteria
Exclusion criteria: - Has other conditions that could interfere with the study, as estimated by physician - Unable to comply with follow-up visits - Allergic to lidocaine and/or adrenaline.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this study is to determine the recurrence rate one month after both procedures have been performed. This rate will be expressed as a percentage of patients who experience a recurrence at the surgical site within one month. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Recurrence rate as a percentage after three and six months. - Recurrence free survival time in days after procedure. - Difference in skin related pain at the surgical site, on a numerical rating scale (NRS), between baseline, week 1, week 2, week 3, month 1, month 3, month 6. - Difference in quality of life measured with the Dermatologic Life Quality Index (DLQI) score, between baseline, month 1, month 3, month 6. - Difference in quality of life measured with the Hidradenitis Suppurativa Quality of Life score (HiSQOL), between baseline, month 1, month 3, month 6. - Treated lesion healing: days till closure. - Difference in number, incidence and severity of adverse events between groups. - Difference in satisfaction score between the two intervention groups at month 6. | — |
Countries
Netherlands
Outcome results
None listed